Tixagevimab-Cilgavimab Treatment and Cardiovascular Events: Immortal Time Bias

被引：1
|
作者：
Montastruc, Francois [1 ,2 ,3 ]
de Canecaude, Claire [1 ,2 ]
机构：
[1] Toulouse Univ Hosp CHU, Fac Med, Ctr PharmacoVigilance & Pharmacoepidemiol, Dept Med & Clin Pharmacol, Toulouse, France
[2] Toulouse Univ Hosp, Ctr Invest Clin 1436, Team PEPSS Pharmacol Populat cohorteS & biobanqueS, Toulouse, France
[3] Toulouse Univ Hosp, Fac Med, Ctr PharmacoVigilance & Pharmacoepidemiol, Dept Med & Clin Pharmacol, 37 Allees Jules Guesde, F-31000 Toulouse, France
来源：
CLINICAL INFECTIOUS DISEASES | 2023年 / 76卷 / 11期
关键词：
D O I：
10.1093/cid/ciad089
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：2044 / 2045
页数：2
相关论文
共 50 条
  • [41] An unjustified benefit: immortal time bias in the analysis of time-dependent events
    Gleiss, Andreas
    Oberbauer, Rainer
    Heinze, Georg
    TRANSPLANT INTERNATIONAL, 2018, 31 (02) : 125 - 130
  • [42] Efficacy and safety of tixagevimab-cilgavimab as pre-exposure prophylaxis for COVID-19: A systematic review and meta-analysis
    Soeroto, Arto Yuwono
    Yanto, Theo Audi
    Kurniawan, Andree
    Hariyanto, Timotius Ivan
    REVIEWS IN MEDICAL VIROLOGY, 2023, 33 (02)
  • [43] SARS-CoV-2 Vaccination Rates and Uptake of Tixagevimab-Cilgavimab Among a Cohort of Pediatric Solid Organ Transplant Recipients
    Reis, Christopher A.
    Ristagno, Elizabeth H.
    Madigan, Theresa
    CLINICAL TRANSPLANTATION, 2024, 38 (07)
  • [44] Assessing the post hoc effectiveness of tixagevimab-cilgavimab for prevention of SARS-CoV-2 infections in solid organ transplant recipients
    Jordan, Stanley C.
    Joung, Sandy Y.
    Wang, Minhao
    Tran, Teresa Anh
    Bravo, Michelle
    Masoom, Hibah
    Chang, Christine
    Mendez, Marilyn
    Patel, Jignesh
    Sun, Nancy
    Kittleson, Michelle
    Frias, Edwin
    Prostko, John C.
    Ebinger, Joseph E.
    Cheng, Susan
    Sobhani, Kimia
    TRANSPLANT INFECTIOUS DISEASE, 2024, 26 (01)
  • [45] Effects of Anti-COVID-19 Vaccination and Pre-Exposure Prophylaxis with Tixagevimab-Cilgavimab in Kidney and Liver Transplant Recipients
    Angelico, Roberta
    Romano, Francesca
    Coppola, Luigi
    Materazzo, Marco
    Pedini, Domiziana
    Santicchia, Maria Sara
    Cacciola, Roberto
    Toti, Luca
    Sarmati, Loredana
    Tisone, Giuseppe
    MEDICINA-LITHUANIA, 2023, 59 (12):
  • [46] Prevalence of Immortal Time Bias in High-Impact Cardiovascular Publications
    Samuel, Michelle
    Kutcher, Stephen
    Flatman, Leah K.
    Emmalin, Buajitti
    Mahmoud, Farida
    Bandargal, Saruchi
    Brophy, Jay
    CIRCULATION, 2022, 146
  • [47] Breakthrough COVID-19 is mild in vaccinated patients with hematological malignancy receiving tixagevimab-cilgavimab as pre-exposure prophylaxis
    Hall, V. G.
    Lim, C.
    Saunders, N. R.
    Klimevski, E.
    Nguyen, T. H. O.
    Kedzierski, L.
    Seymour, J. F.
    Wadhwa, V.
    Thursky, K. A.
    Yong, M. K.
    Kedzierska, K.
    Slavin, M. A.
    Teh, B. W.
    LEUKEMIA & LYMPHOMA, 2023,
  • [48] Real-world effectiveness of prophylactic tixagevimab-cilgavimab monoclonal antibodies on incidence and severity of COVID-19 infection in patients with cancer
    Naser, Maryam
    Bhardwaj, Prarthna V.
    Warriach, Fatima Zahid
    Jadoon, Yamna
    Gupta, Kush
    Rastegar, Vida
    Loke, Chandravathi
    Malleshappa, Sudeep Kumar Siddappa
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [49] Evaluating the Cardiovascular Event Profile After Administration of Tixagevimab and Cilgavimab (Evusheld) in Lung Transplant Recipients
    Bulger, J. L.
    Ching, K.
    Joyce, C.
    Warrior, K.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 207
  • [50] Reduced prophylactic effect of tixagevimab-cilgavimab in patients with hematological malignancies and without antibody response after SARS-COV-2 vaccination
    Callegari, Chiara
    Lazzarotto, Davide
    Soravia, Alessandra
    Mutti, Martina
    Lauzzana, Pietro
    Peghin, Maddalena
    Cordella, Stefano
    Fanin, Renato
    Candoni, Anna
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2023, 111 (04) : 668 - 670
12345